Markers associated with sex differences in methamphetamine-induced striatal dopamine neurotoxicity.

Markers associated with sex differences in methamphetamine-induced striatal dopamine neurotoxicity.

Dluzen D E; McDermott J L; Bourque M; Di Paolo T; Darvesh A S; Buletko A B; Laping N J

Current neuropharmacology

2011

2011-03

Three different approaches were employed to assess various markers associated with sex differences in responses to methamphetamine (MA). Bioassay measures reveal that MA treatment results in significantly greater reductions in body weight and increases in body temperature in male mice. Protein and mRNA determinations show significant increases in Bcl-2 and PAI-1 in male mice, while females show significant increases in GFAP and decreases in IGF-1R following treatment with MA. In mice with a heterozygous mutation of their dopamine transporter (+/- DAT), only female mice show significant differences in dopamine transporter binding and mRNA and associated reductions in striatal dopamine content along with increases in MA-evoked striatal dopamine output. The identification of these sex-dependent differences in markers provides a foundation for more exhaustive evaluation of their impact upon, and treatment of, disorders/neurotoxicity of the nigrostriatal dopaminergic system and the bases for the differences that exist between females and males.

Body Temperature; Body Weight; Bcl-2 PAI-1; Dopamine Transporter.; GFAP; IGF-1R

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

40–44

1

9